

someday is today

LLS exists to find cures and ensure access to the best available treatments for all blood cancer patients.

Last year alone, LLS invested nearly \$74 million in cutting-edge research.

For more than 60 years LLS has invested more than \$1 billion to advance cancer therapies and save lives.

Nearly 40% of new cancer therapies approved by the FDA between 2000 and 2013 were first approved for blood cancer patients.

LLS has helped advance laws in more than half of the states to ensure coverage and payment parity for cancer medications, regardless of how or where administered.

Since the early 1960s, five-year survival rates for many blood cancer patients have doubled, tripled or even quadrupled.

In 1964, the five-year survival rate for children with the most commonly diagnosed leukemia was 3%. Today it's approximately 90%.

Since LLS's inception 65 years ago, cures for many patients with acute lymphoblastic leukemia and Hodgkin lymphoma have been achieved.

Hodgkin lymphoma survival rates more than doubled, to 87%, since the 1960s.

The survival rate for myeloma more than tripled since the 1960s.

LLS helped advance targeted therapies for patients with chronic myeloid leukemia; this oral drug is now helping patients with other cancers.

LLS-funded research teams at multiple institutions are testing different approaches to activate the immune system to kill cancer cells.

LLS-funded teams have helped advance FDA-approved targeted therapies to treat patients with chronic lymphocytic leukemia and other B-cell cancers.

LLS-funded researchers helped advance an antibody therapy that helps boost the immune system to attack cancer cells in patients with lymphoma and chronic lymphocytic leukemia.

LLS partners with academic centers and biotechnology companies to get new treatments to more patients, faster.

LLS advocates for state and federal legislation to ensure patients have access to quality, affordable and coordinated care.

Blood cancers can affect cells in the blood, bone marrow, the spleen, lymph nodes and other parts of the lymphatic system.

More than 1.1 million people in the US are living with, or are in remission from, a blood cancer.

Multi-drug chemotherapy was first successfully developed for blood cancer patients.

Stem cell transplantation was first used as a treatment for leukemia patients.

LLS helped advance therapies for myeloma and lymphoma patients, and some of these drugs are also being tested for patients with other cancers.

LLS's Information Resource Center has touched more than 1 million callers since its inception in 1997.

Last year, Information Resource Center (IRC) specialists fielded more than 62,000 inquiries and performed more than 6,000 clinical trial searches using the IRC's TrialCheck tool.

Last year LLS's Information Resource Center expanded its hours to 9 am to 9 pm Eastern Time.

LLS's Information Resource Center can assist callers in English, Spanish and French, with translations available in 140 other languages.

LLS's Team In Training® continues to be the leader in charity endurance training programs.

LLS is the leading source of free blood cancer information, education and patient support.

We have one goal: A world without blood cancers.

Today we are closer than ever to cures for many kinds of blood cancers. We are at the brink of life-changing breakthroughs. We can see the end of cancer from here. Join us.